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Previously, we used cDNA microarrays to demonstrate that the phosphatidylinositol and MAP kinase signaling pathways are regulated by
nicotine in different rat brain regions. In the present report, we show that, after exposure to nicotine for 14 days, ubiquitin, ubiquitin-
conjugating enzymes, 20S and 19S proteasomal subunits, and chaperonin-containing TCP-1 protein (CCT) complex members are
upregulated in rat prefrontal cortex (PFC) while being downregulated in the medial basal hypothalamus (MBH). In particular, relative to
saline controls, ubiquitins B and C were upregulated by 33% and 47% (Pb0.01), respectively, in the PFC. The proteasome beta subunit 1
(PSMB1) and 26S ATPase 3 (PSMC3) genes were upregulated in the PFC by 95% and 119% (Pb0.001), respectively. In addition to the
protein degradation pathway of the ubiquitin–proteasome complexes, we observed in the PFC an increase in the expression of small,
ubiquitin-related modifiers (SUMO) 1 and 2 by 80% and 33%, respectively (Pb0.001), and in 3 of 6 CCT subunits by up to 150%
(Pb0.0001). To a lesser extent, a change in the opposite direction was obtained in the expression of the same gene families in the MBH.
Quantitative real-time RT-PCR was used to validate the microarray results obtained with some representative genes involved in these
pathways. Taken together, our results suggest that, in response to systemic nicotine administration, the ubiquitin–proteasome, SUMO, and
chaperonin complexes provide an intricate control mechanism to maintain cellular homeostasis, possibly by regulating the composition and
signaling of target neurons in a region-specific manner.
D 2004 Elsevier B.V. All rights reserved.
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Nicotine is a potent agonist affecting various cellular
processes throughout the brain. Acting on a diverse set of
nicotinic acetylcholine receptors (nAChRs), nicotine can
directly modulate the signaling pathways of a target neuron.
Nicotinemay also have indirect actions through influences on
the release or uptake of neurotransmitters surrounding the
parenchyma. The cellular and physiological consequences of
nicotine’s actions within the central nervous system (CNS)0169-328X/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.molbrainres.2004.09.010
* Corresponding author. Tel.: +210 567 0830; fax: +210 567 0853.
E-mail address: lim2@uthscsa.edu (M.D. Li).are substantial and diverse. Although numerous in vitro and
in vivo studies have been conducted to investigate how a gene
of interest is modulated by nicotine, changes in gene
expression profiles during acute and chronic exposure to
the drug have been largely unknown.
The recent development of microarray technologies,
allowing comparison of expression profiles of thousands
of genes simultaneously, has revolutionized almost all
biomedical research fields, including nicotine abuse
research [16,28,37]. Previously, by using cDNA micro-
arrays, we have shown that several genes such as rap 1,
Homer, and NF-kB and biochemical signaling pathways
such as phosphatidylinositol and JNK cascades may play132 (2004) 181–191
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same approach, in an accompanying paper [34], we
followed the expression levels of 638 sequence-verified
genes in five regions of the rat brain over time to gain a
better understanding of how nicotine influences the molec-
ular environment in physiologically pertinent brain regions.
Nicotine, a potent nAChR agonist, is likely to produce an
altered environment within the CNS, forcing neurons to
adapt. Onemechanism used by the cell to sustain homeostasis
under new environmental conditions is the ubiquitin–
proteasome pathway [21]. Ubiquitin is a conserved protein
known to target proteins for degradation by the 26S
proteasome complex. Because of the specificity of ubiquiti-
nation, ubiquitin is responsible not only for targeting
denatured proteins but also proteins that are intact but
regulated in a time- or region-dependent manner. Through
the destruction of these key signal proteins, the ubiquitin
system is an important component of many signaling path-
ways [55]. For example, ubiquitin-mediated protein degra-
dation controls cell cycle progression, signal transduction,
transcriptional regulation, receptor downregulation, and
endocytosis [12,13,21]. Moreover, under stress, proteins
may become denatured and nonfunctional, producing an
environment that may be cytotoxic. The ubiquitin/proteaso-
mal system thus has a primary role in maintaining a healthy
cellular environment by minimizing the accumulation of
denatured and nonfunctional proteins. Secondarily, the
system can play a key role in signaling pathways by targeting
their rate-limiting proteins for destruction. An example of the
impairment of the ubiquitin/proteasome system by a drug of
abuse is ethanol’s ability to partially inactivate the protea-
some and block the ubiquitination of protein targets [7,15].
Whereas the ubiquitin/proteasome pathway targets pro-
teins for destruction, chaperones are involved in the folding
of newly synthesized proteins as well as refolding of
proteins denatured under environmental stress. The chaper-
onin-containing TCP-1 (CCT) is a subclass of the chaper-
onin protein family that aids in the folding of large
nonnative proteins [19,31]. For example, CCT has a
hetero-oligomeric structure that helps to create the correct
3-D structure of cytoskeletal proteins such as actin, tubulin
and other polypeptides in the cytosol [51]. Because of its
constructive functionality, CCT is likely to work in concert
with other protein modification and degradation pathways
for the plasticity and maintenance of cellular homeostasis.
These multiple pathways are known to crosstalk and are
the product of interconnected gene networks. Our previous
investigations have demonstrated the value of microarrays in
tracking nicotine-induced changes in expression of genes that
belong to the phosphatidylinositol-driven pathways, both in
the brain and in PC-12 cells [28,37]. These initial findings
implicated nicotine as an important modulator of cellular
homeostasis, thus warranting its further study in relation to
other homeostatic pathways such as those of protein
modification and degradation. In this study, we focused on
investigating the correlation of mRNA transcription profilesof proteinmodification/degradation complexes with subacute
and chronic exposure to nicotine (i.e., 3 and 14 days) within
the prefrontal cortex (PFC) and the medial basal hypothal-
amus (MBH). Our results revealed that ubiquitin–protea-
some, SUMO, and CCT complex members contribute to the
changes induced by nicotine in a region- and time-specific
manner. We present the first report of the involvement of
multiple yet interconnected cellular pathways of protein
modification and degradation in response to chronic admin-
istration of nicotine in rat PFC and MBH.2. Materials and methods
2.1. Animals, nicotine administration, and brain punches
Male Holtzman rats (250–350 g; HSD, Madison, WI)
received either nicotine dihydrochloride at a dose of 4.0 mg/
kg/day in saline (pH 7.4) or saline alone by intraperitoneal
(ip) injection. The rats quickly became tolerant to the dose,
and no seizures were observed [24,36]. An initiation phase
of 48 h was used to habituate the animals to the stress of the
injection, as confirmed by reduction of c-fos expression
[47]. Rats were maintained on a 12:12 h light/dark cycle
with standard laboratory rat chow and water freely
available.
After the conclusion of nicotine administration, rats were
injected with a lethal overdose of sodium pentobarbital (100
mg/ml; ip) and decapitated, and their brains were removed.
Coronal 2-mm sections were prepared, and bilateral speci-
mens were obtained from the PFC and MBH using a brain
punch tissue set from myNeuroLab.com (St. Louis, MO) at
sites chosen according to the coordinates from Paxinos and
Watson [45].
2.2. Total RNA isolation and amplification
Total RNA was isolated using TRIzol reagent according
to the manufacturer’s protocol (Qiagen, Valencia, CA).
Before use, RNA samples were treated with RNAse-free
DNAse I at 37 8C for 30 min. The integrity of the samples
was assessed by viewing the ethidium bromide-stained 28S
and 18S ribosomal RNA bands. AT7 amplification protocol
was used to produce the amount of starting RNA required
for the synthesis of fluorescent cDNA probes [54].
2.3. Microarray production, cDNA probe labeling, and
array hybridization
A pathway-focused microarray consisting of 638
sequence-verified genes that was designed by our laboratory
(called the homeostatic pathway-focused array) was used
[52]. This array contains 638 sequence-verified genes
selected from rat cDNA clones (Research Genetics, AL)
and the 15K NIA mouse cDNA gene set [52] on the basis of
our previous studies [28,37]. It was shown that cross-species
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using a cDNA platform is accurate and specific [59]. Cells
containing the cDNA clones of interest were grown over-
night, and 10 Al of the culture medium plus 90 Al of water
were incubated at 95 8C for 10 min to release plasmid DNA.
A 10-Al sample of supernatant liquid was added to a PCR
cocktail mixture containing Taq polymerase in a total
volume of 100 Al. The reaction mixtures were denatured
at 95 8C for 3 min and then subjected to 35 cycles of
denaturation, annealing, and extension. The products were
ethanol precipitated, washed and reconstituted in TE buffer.
To increase the reliability of the measurements, 30 Al of
80% dimethyl sulfoxide (DMSO; Sigma) was added to the
dissolved PCR products. The slides were printed by the
GMS 417 arrayer (Affymetrix, Santa Clara, CA) according
to the protocols suggested by the manufacturer. cDNA
probe labeling and array hybridization were performed as
described previously with slight modifications [28,29].
2.4. Microarray data normalization and statistical analysis
The procedures used for normalization and detection of
significantly expressed genes were described in detail
previously. For any given time point of treatment, we
started the experiments with six control and six nicotine-
treated animals. However, for some regions, the final
number of RNA samples or microarray hybridizations/slides
was less because we lost some samples during the animalTable 1
Summary of selected genes and their primer information used in quantitative rea
Gene name Abbreviation
Proteasome subunit, beta Type 1 Psmb1
Proteasome subunit, beta Type 3 Psmb3
Proteasome subunit, beta Type 2 Psmb2
Proteasome ATPase p45/SUG SUG1
Proteasome 26S subunit, ATPase 3 Psmc3
Proteasome subunit 26S, non-ATPase 4 Psmd4
Proteasome 26S subunit, non-ATPase 13 Psmd13
Rat ubiquitin B-like rUbb
Ubiquitin-conjugating enzyme 5 Ube2e1
Ubiquitin-like protein 1 SUMO-1
Ubiquitin-like protein 2 SUMO-2
Ubiquitin-conjugating enzyme E2I Ube2I
Chaperonin subunit 3 (gamma) CCT3
Chaperonin subunit 7 (beta) CCT7experiments, did not have enough RNA for probe labeling,
or eliminated slides because the overall duplicate spot
correlation coefficient value was b0.9. Ultimately, the PFC
had three controls and two nicotine-treated animals at day 3
and three control and three nicotine-treated animals at day
14, while the MBH had three control and five nicotine-
treated animals at day 3 and five control and five nicotine-
treated animals at day 14. Given that each gene was printed
in duplicate on the array, expression of the genes reported
was derived from at least four independent measurements.
Analysis of variance was used to test the significance of
differentially expressed genes. All these processes involving
data normalization and analysis were performed in programs
written in MatLab (Mathworks, Natick, MA) or SAS (SAS
Institute, Cary, NC).
2.5. Validation of microarray results by real-time quantita-
tive RT-PCR
Microarray results were validated with real-time quanti-
tative RT-PCR using a strategy described previously [35]
with modifications [8,28]. After the last cycle, a dissociation
curve was run to check for product purity. The expression
level of each gene was determined after specifying an
amplification cycle corresponding to the exponential growth
phase of the RT-PCR reaction for that gene. Intensity values
based on the incorporation of fluorescent SYBRR Green
dye (excitation/emission 497/520 nm) into the double-l-time RT-PCR amplification
Accession no. Primer sequence (5VY3V)
BC018351 P1:GCA TCA GGG AGG AGA CTG TT
P2:TAA AAC AAA CGT GCC ACA GT
BC014783 P1:GCG TCA TTG TCC ACA TCA TT
P2:GCC AGA GCA CAG GTT AGT CC
AF060090 P1:CCC CCA CAG CAG CAG CTA AT
P2:AGC CAG CCA GGA GGA GGT TC
AB000491 P1:AAC CAG CTG GAT GGC TTT GA
P2:GCA GGG CAG AGT CCA GGA TA
NM_031595 P1:GAC CTG GAC TCG CAG AGG AA
P2:AAC CCA ATC ACT GGC AGG AA
NM_031331 P1:CAG GAC CCA GAG TTC CTT CA
P2:ATT GCA TTT CGA ATG GCT TC
NM_011875 P1:GTT TGG CAC CGT TTG GAA GA
P2:GCA TGG GTC CTG CAC AAA AT
D16554 P1:TGA GGA CTG CAG CCA ACA CC
P2:GGT GTC ACT GGG CTC GAC CT
BC003781 P1:GGC CAG ACA GTG GAC CAA GA
P2:CAC CCC CAC CCT TTC AAA AT
NM_009460 P1:CCA GGA GGC AAA ACC TTC AAC
P2:CAC TGC TAT CCT GTC CAA TGA C
NM_133594 P1:GGG ACA GGA TGG TTC TGT GG
P2:CAA ACC CTG CCG TTC ACA AT
NM_013050 P1:GAC TTG CGC AGG AGA GGA AA
P2:TCG TGC CAT CAG GGT TCT TT
Z31556 P1:AGA TGC TGG CCA GGA GTG AG
P2:TCC TGG AAC TCT GGC TCA GG
Z31399 P1:GGA CAT TGC TGA CAA CTT CC
P2:CAG GCA CGC AGC CTC AGA AG
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were measured at these specified amplification cycles. All
genes were normalized to the 18S rRNA level. The primer
sequences used for PCR amplification in conjunction with
other related information are summarized for each gene in
Table 1.
All of the techniques used are described in detail
elsewhere (Refs. [28,29,34]).3. Results
3.1. Upregulation of ubiquitin and SUMO gene families in
the PFC after 14 days of nicotine administration
In the rat, two main transcripts encode ubiquitins B and
C [18,20]. Our pathway-focused microarray contains three
ubiquitin-derived clones; two are mouse ubiquitins B and
C, and the third is a rat ubiquitin homologous to mouse
ubiquitin B. In the PFC, we observed an increase in
mRNA expression for mouse ubiquitins B and C and the
rat ubiquitin B after 14 days of nicotine administration
(33%, 47%, 38%, respectively; Pb0.01 for all of them;
Table 2).
In addition to ubiquitin expression, upregulation of
ubiquitin-conjugating E2 mRNAs was observed. For exam-
ple, we found that nicotine treatment increased ubiquitin-
conjugating enzyme E2I (Ube2I) expression by 37%
(Pb0.01; Table 2) and ubiquitin protein ligase E3B (Ube3b)
expression by 21% (P=0.08) in the PFC. Except for a
modest increase in ubiquitin fusion degradation 1 at day 3
(12%; Pb0.05), the ubiquitin gene family did not show a
significant response to nicotine in the PFC after 3 days of
treatment.
While SUMO is activated and targets substrate proteins
in a fashion analogous to ubiquitin, the fate of the substrate
being sumoylated is different. SUMO-1 modulates theTable 2
Expression of ubiquitin and SUMO-related protein genes in PFC at 3 and 14 day
Gene name Abbreviation
Ubiquitin fusion degradation 1 Ufd1l
Ubiquitin-specific protease 5 Usp5
Ubiquitin-like 1 SUMO-1
Ubiquitin C Ubc
Ubiquitin specific protease 8 Ubp8
Ubiquitin A-52 residue ribosomal protein fusion product 1 Uba52
Rat ubiquitin B-like rUbb
Ubiquitin-conjugating enzyme E2I Ube2I
Ubiquitin-like 2 SUMO-2
Ubiquitin B Ubb
Ubiquitination factor E4B Ube4b
Ubiquitin-specific protease Usp2
Ubiquitin-conjugating enzyme 5 Ube2e1
* Pb0.05.
** Pb0.01.
*** Pb0.001.interaction of the target protein with other cellular proteins
and often results in changing the protein’s location
[9,27,43]. For example, a SUMO-attached protein may be
transported to the nucleus [27,39]. Furthermore, there exist
functional differences between SUMO-1, SUMO-2 and
SUMO-3, such that a greater abundance of SUMO-2 and
SUMO-3 acts as a stress response compared with SUMO-1
[48]. After 14 days of nicotine administration, both SUMO-
1 and SUMO-2 were modulated with an increase in
expression by 79% (Pb0.0001) and 33% (Pb0.001; Fig.
1), respectively. These findings have been confirmed by
quantitative real-time RT-PCR (see Fig. 5 below). Further-
more, expression of Ube2I/Ubc9, the only E2 enzyme of
sumoylation, was significantly (37%) upregulated in the
PFC (Pb0.001; Table 2).
3.2. Upregulation of proteasome-complex genes in the PFC
after 14 days of nicotine treatment
Once a protein has been ubiquitinated, it is brought to the
26S proteasome containing the 20S catalytic core and two
19S regulatory complexes for degradation. The mammalian
20S proteasome is made up of seven different alpha and
seven different beta subunits, with the beta subunits
comprising the inner rings, where the actual cleavage of
proteins occurs. Our array results demonstrated an increase
in proteasome subunits: beta type 1 after 3 (39%; Pb0.05)
and 14 (95%; Pb0.0001) days of nicotine administration
and beta type 2 (21%; P=0.01) and beta type 5 (33%;
Pb0.05; see Table 3) after 14 days.
The 19S complex is made up of different ATPase and
non-ATPase subunits that aid in regulating the 20S complex.
On day 14, we found an increase in the ATPase subunit 3
(119%; Pb0.0001) and ATPase subunit SUG1/P45 (39%;
Pb0.05; see Table 3). Significant increases in non-ATPase
subunits 4 (60%; Pb0.01) and 13 (94%; Pb0.0001) also
were detected on day 14.s of nicotine administration, as determined by microarray analysis

















Fig. 1. Expression of ubiquitin-related genes in MBH at 3 and 14 days of nicotine administration, as determined by microarray analysis. (A) Expression of
ubiquitin-related genes is upregulated significantly at 3 days. (B) Expression of genes of several ubiquitin-conjugating enzymes of this family is significantly
downregulated at 14 days. Abbreviations: ubiquitin protein ligase E3B (Ube3b, BC034059); ubiquitin-specific protease 8 (Usp8, BC027052); ubiquitin-
conjugating enzyme E2I (Ube2I, NM_013050); ubiquitin-like 1 (SUMO-1, NM_009460); ubiquitin-specific protease 25 (Usp25, AF170563); ubiquitin-
conjugating enzyme 5 (Ube2e1, BC003781); ubiquitin-specific protease 9 (Usp9x, NM_009481), ubiquitin-conjugating enzyme E2b (Ube2b, AF144083).
Significance level: *Pb0.05, **Pb0.01, ***Pb0.001.
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MBH decreases over 14 days of nicotine administration
The MBH is a structurally diverse brain region involved
in a variety of physiological functions. While we observed a
transient increase in expression of the ubiquitin family genes
in the MBH on day 3 (Fig. 1A), this increase was followed
by a significant decline in expression of several ubiquitin-
conjugating enzymes on day 14 (Fig. 1B). Indeed,
proteasome subunits alpha 2 (15%; Pb0.01), 3 (15%;
Pb0.01) and 6 (8%; Pb0.01) were all downregulated after
14 days of nicotine treatment (Fig. 2), contrasting with the
pattern we observed for the set of proteasome beta subunits
in the PFC at the same time point.
3.4. Chaperonin subunits are upregulated in the PFC but
downregulated in the MBH after 14 days of nicotine
treatment
There are many families of chaperones (e.g., heat shock
proteins; for a review, see Ref. [19]). Our pathway-focusedTable 3
Expression of proteasome-related protein genes in PFC at 3 and 14 days of nicot
Gene name Abbreviation Acces
Proteasome 26S, ATPase 3 Psmc3 NM_
Proteasome 26S, non-ATPase, 13 Psmd13 NM_
Proteasome subunit, beta type 1 Psmb1 BC01
Proteasome 26S, non-ATPase, 4 Psmd4 NM_
Proteasome subunit, beta type 5 Psmb5 AF06
Proteasome ATPase p45/SUG SUG1 AB00
Proteasome 26S, ATPase 5 Psmc5 BC03
Proteasome subunit, beta type 2 Psmb2 AF06
* Pb0.05.
** Pb0.01.
*** Pb0.001.array contains sequences encoding five of the eight subunits
that make up the chaperonin-containing TCP-1 protein
(CCT). Chaperonin subunits 3 (120%; Pb0.0001), 7 (158%;
Pb0.0001), and 8 (70%; Pb0.0001) were upregulated in the
PFC at 14 days of nicotine treatment (Fig. 3). In contrast,
chaperonin subunits 2 (16%; Pb0.01), 3 (12%; Pb0.01), 4
(16%; Pb0.05), and 8 (22%; Pb0.001) were downregulated
in the MBH (Fig. 4). No significant differences were
observed in the chaperonin gene family expression in the
PFC or MBH after 3 days of nicotine administration.
3.5. Quantitative real-time RT-PCR confirms a majority of
genes identified by microarray analysis
The microarray results were validated using quantitative
real-time RT-PCR with representative gene-specific primers
on RNA samples extracted from an independent animal
experiment. Primer sequences were selected according to
the cDNA sequence printed on the microarray (see Table 1
for a detail). Fig. 5 shows side-by-side comparisons of real-
time RT-PCR and microarray data of nine genes in the PFCine administration, as determined by microarray analysis












Fig. 4. Expression of chaperonin-related protein genes in MBH at 3 and 14
days of nicotine administration (*Pb0.05). The CCT subunits 2, 3, 4, and 8
are downregulated by approximately 12% to 22%. While downregulation is
modest (possibly because of diluting effects of a diverse structure), the
nicotine effect on four subunits (with seven of the eight subunit genes
printed on the array) indicates a stronger correlation for downregulation of
this complex. Significance level: *Pb0.05, **Pb0.01, ***Pb0.001.
Fig. 2. Expression of genes for several alpha subunits from 20S proteasomal
complex in MBH at 3 and 14 days of nicotine administration, as determined
by microarray analysis. Expression of most of these alpha subunits is
downregulated at 14 days. No significant differences were obtained at 3
days. Abbreviations: proteasome subunit, alpha 6 (Psma6, U60288);
proteasome subunit, alpha 2 (Psma2, NM_008944); proteasome subunit,
alpha 3 (Psma3, AF055983); proteasome-associated pad1 (Poh1,
BC003742). Significance level: *Pb0.05, **Pb0.01.
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PCR confirmed the significant increases in the expression of
rat polyubiquitin (26%; Pb0.05), SUMO-1 (20%; P=0.08)
and SUMO-2 (37%; Pb0.05; Fig. 5A). The real-time RT-
PCR results for the selected CCT components (Fig. 5B)
showed 20% and 25% (Pb0.05) increases in subunits CCT3
and CCT7, respectively. For the different proteasome
subunits, the RT-PCR confirmed the increase in the beta
type 1 subunit (46%; Pb0.05), 26S subunit ATPase 3 (39%;Fig. 3. Expression of chaperonin-related protein genes in PFC at 3 and 14
days of nicotine administration, as determined by microarray analysis.
Significant changes were obtained for subunits 3, 4, 7, and 8 at 14 days.
Abbreviations: chaperonin subunit 3 (CCT3, Z31556); chaperonin subunit
4 (CCT4, NM_009837); chaperonin subunit 7 (CCT7, Z31399) and
chaperonin subunit 8 (CCT8, Z37164). Significance level: *Pb0.05,
**Pb0.01, ***Pb0.001.Pb0.05), and 26S subunit non-ATPase 13 (27%; Pb0.05)
and demonstrated an upward trend for the SUG1 gene (22%;
P=0.07; Fig. 5C).4. Discussion
In addition to identifying candidate genes of interest for
further molecular characterization such as traditional library
screening or differential display, chip technology has
another powerful application; i.e., to investigate how a
group of function-related genes within a biochemical
pathway respond to a treatment. One of the primary
purposes of this communication is to illustrate such an
application of microarrays in nicotine research. Protein
synthesis and degradation are dynamic processes controlled
by numerous factors and at different levels. For example, a
cell may utilize the ubiquitin–proteasomal pathway to
control the duration that a protein remains intact. As a
result of its widespread utility, the ubiquitin–proteasomal
pathway is complex, with many proteins required to work in
concert. By using the pathway-focused microarray devel-
oped in this laboratory, we found a number of genes from
the ubiquitin–proteasome and SUMO pathways, as well as
the CCT gene family, that are highly regulated by chronic
nicotine exposure in the rat PFC and MBH.
Our pathway-focused microarray analyses indicated an
increase in the expression of several members of the
ubiquitin and proteasome gene families in the PFC with
nicotine administration. In the PFC, both major ubiquitin B
and C transcripts were upregulated at day 14. In addition,
the expression levels of ubiquitin-conjugating enzymes,
ubiquitin-specific proteases, and deubiquitinating enzymes
were upregulated, suggesting a general activation of the
Fig. 5. Comparison of microarray and quantitative real-time RT-PCR results of selected genes in PFC after 14 days of nicotine administration. (A) Expression
of ubiquitin and ubiquitin-related genes. (B) Levels of chaperonin subunits. (C) RNA levels of proteasomal-related genes. Verification of selected genes by
real-time RT-PCR was performed in an independent animal experiment. For abbreviations, see Table 1.
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menting the increase in the ubiquitin system, there was an
increase in expression of 20S proteasome subunits and of
regulatory subunits of the 19S complex. The expression
levels of two of the six ATPase subunits from the 19S base
complex were upregulated as well, possibly indicating an
increase in the need to provide the energy required in
forming the 26S proteasome.
In contrast to the PFC region, in the MBH, members of
the ubiquitin–proteasome gene families were downregulated
after 14 days of nicotine administration. Three alpha
subunits of the 20S complex were downregulated by
approximately 10% to 15%. While no ubiquitin or SUMO
genes were differentially regulated at 14 days, expression of
two ubiquitin-conjugating and one SUMO-conjugating
enzymes was decreased. Such differential responses to
nicotine support the concept that various brain regions
participate in different cellular and physiological functions.
Indeed, a gene expression profiling study demonstrated
similar profiles in subnuclei of the same brain region (i.e.,
Ca1 and Ca3 of the hippocampus) but very different profiles
in different brain regions (i.e., hypothalamus and hippo-
campus) [6]. Because different regions of the brain are
divergent in their cellular compositions (i.e., neurotransmit-
ter release, receptor expression, intracellular signalingcascades) to manage specific physiological activities, a
region-specific transcriptional response of ubiquitin–protea-
some signaling to nicotine treatment would be expected.
The ubiquitin–proteasome pathway is responsible for the
majority of intracellular protein degradation. Thus, it
functions in a variety of capacities, all of which aim to
produce protein homeostasis under different conditions.
While the ubiquitin–proteasome pathway is constitutively
involved in protein degradation, there are several known
activation signals leading to its upregulation. For example,
environmental and oxidative stresses that damage proteins
activate the transcription of ubiquitin by increasing ubiquitin
B and C transcripts [18] and converting free ubiquitin to a
conjugated pool [11,21]. Although drugs of abuse, such as
alcohol, nicotine and cocaine, induce oxidative damage and,
hence, cellular stress [4,10,57] , the involvement of the
ubiquitin–proteasome pathway in the response to nicotine
treatment has remained largely unexplored. Because nic-
otine produces oxidative stress, protein denaturation and
aggregation may be underlying effects the cell must combat
[56,57]. Thus, protein modification/degradation pathways
may be forced to respond to the changing conditions of the
cell to produce homeostatic levels of proteins (see Fig. 6 for
a proposed model). Furthermore, the observation that the
CCT and ubiquitin–proteasome gene families are both
J.K. Kane et al. / Molecular Brain Research 132 (2004) 181–191188upregulated in the PFC but downregulated in the MBH
points to a common response element for the two gene
families in these brain regions responding to the altered
cellular environment brought about by nicotine.
Another pertinent role for the ubiquitin/proteasomal
system has been demonstrated by Ehlers [17], who showed
the regulation of numerous postsynaptic proteins by
ubiquitination in response to synaptic activity in cultured
rat hippocampal neurons. Recently, the ubiquitination
process was linked to the regulation of the assembly and
cell-surface trafficking of nAChRs [25,26]. We propose that
nicotine increases synaptic activity while simultaneously
producing a state of oxidative stress within certain areas of
the brain. This, in turn, may lead to the modulation of the
ubiquitin–proteasome pathway in an effort to maintain
appropriate levels of functional proteins needed for the
altered level of cellular homeostasis in the presence of
nicotine. The ubiquitin–proteasome system may accomplish
this task by getting rid of denatured proteins as well as
acting by as a regulator of other signaling pathways and/or
through regulating the density of receptors such as the
nAChRs (Fig. 6).
In this study, 3 and 14 days of nicotine administration
were used to study the subacute and chronic effects of
nicotine, respectively. The route of administration was
chosen to ensure equal amounts of nicotine or saline given
in an identical manner, thereby reducing potential exper-
imental errors in the measured gene expression levels,
which were induced by variation among animals. While it
does not mimic human smoking exactly, this protocol does
reproduce the cyclical levels of plasma nicotine concen-
tration observed in smokers between waking and sleepingFig. 6. Proposed model for nicotine’s effects on protein modification and degrad
cause DNA damage. This effect may modulate the systems (both DNA and protein
ubiquitin/proteasomal system involved in protein degradation, SUMOs and ubiquit
result is the potential regulation of signaling pathways determining chromosomal in
of SUMO/Ubc9 in connection with ubiquitin/RAD6 and/or chaperonin systems m
response to nicotine.hours [2,3,36]. By using an initiation phase for habituation
and an appropriate saline-control group, we believe the
stress of ip injection has been taken into account, which has
been documented in the c-fos expression study [47]. Indeed,
this dose and method of administration have been utilized
effectively in a number of research laboratories (e.g., see
Refs. [2,3,14,36,40]).
While there was upregulation of many ubiquitin genes in
the MBH after 3 days of nicotine administration, in general,
the ubiquitin–proteasomal gene families demonstrated
coregulation in the MBH and PFC after 14 days. This
suggests that a chronic effect of nicotine is required within
these brain regions before the ubiquitin–proteasomal gene
families are regulated. Whether the increase in expression of
ubiquitins B and C and other members of the ubiquitin and
proteasome families in the PFC and MBH is the direct result
of nicotine’s oxidative stress effect or an indirect effect of
increased synaptic activity over time is unclear. Further
study will be required to decipher the biochemical mech-
anism(s) by which the ubiquitin–proteasome pathway is
activated in response to nicotine.
While SUMO activation and substrate targeting has
analogy with the ubiquitin pathway, the final destination
of sumoylated proteins is not the 26S proteasome. SUMO
proteins often compete with ubiquitin for the same
substrates, but once sumoylated, the protein may be trans-
ferred to the nucleus [27]. From the findings of the present
study, the upregulation of both SUMO-1 and SUMO-2, and
Ubc9 along with the activation of the ubiquitin system in the
PFC at day 14 of nicotine exposure strongly suggests that
the two pathways are competing for the same protein
substrates (Fig. 6). The CCT is a hetero-oligomeric complexation pathways. Nicotine administration produces oxidative stress and may
) responsible for maintaining homeostasis within the cell. These include the
in in DNA repair, and the chaperonin system that aids in protein folding. The
tegrity as well as the fate of aggregated or key signal proteins. Involvement
ay ultimately play a role in the survival signals in cells (e.g., neurons) in
J.K. Kane et al. / Molecular Brain Research 132 (2004) 181–191 189made up of eight highly conserved subunits regulated in
concert to maintain a constant ratio so that the complex is
best formed in a fixed-subunit composition [32,33]. An
increase of three CCT subunits in the PFC and a decrease of
four CCT subunits in the MBH support the idea of
coordinate regulation of CCT subunits at the transcription
level. Furthermore, protein degradation of CCT is controlled
by the ubiquitin–proteasome system [58]. In the PFC, the
proteasome system may degrade CCT subunits to force
upregulation of CCT gene transcription in order to keep
pace with the demands of the cell. It seems that these two
pathways are working jointly to promote protein homeo-
stasis in a cell under oxidative stress.
Previous studies also have suggested that nicotine,
directly or indirectly, modulates the amount of DNA repair
and/or DNA damage tolerance [30,44,46]. For example,
nicotine increases the repair of plasmid DNA damaged by
free radicals in the presence of whole-cell protein extracts
from adult myocytes [30]. The authors postulated that
nicotine enhances DNA degradation through increasing
nuclease activity, which allows more efficient incorporation
of nucleotides needed to repair the damaged DNA [30]. On
the other hand, a recent study suggested nicotine has
protective effects against DNA-damaging agents in head
and neck cancer cell lines through a decrease in the activity
of stress-activated protein kinase signaling (SAPK/JNK)
[44]. In the presence of nicotine, it is likely that the DNA
repair machinery is forced to cope with damage resulting
from production of reactive oxygen species [25,26]. Never-
theless, the exact molecular mechanisms underlying nic-
otine’s effect on DNA repair and DNA damage tolerance
remain largely unknown and controversial. Recent evidence
strongly implicates ubiquitination and sumoylation in DNA
replication/repair and damage tolerance [22,50].
In this context, the SUMO/Ubc9 pathway has been
shown to compete with the ubiquitin/RAD6 pathway in
fine-tuning the extent to which the cell practices DNA
repair. Furthermore, DNA repair is essential in maintaining
chromosome integrity and attaining an appropriate cell fate
(apoptosis vs. survival). Recent studies indicate that the
ubiquitin/proteasome pathway, as well as sumoylation and
modification of tubulin by the CCT complex, contributes to
the maintenance of chromosomal integrity [1,5,23,49,53].
According to the proposed model illustrated in Fig. 6, we
hypothesize that the observed increase in the PFC of
expression of mRNA for both the ubiquitin/RAD6 and
SUMO/Ubc9 genes after nicotine exposure may be indica-
tive of a sustained response to an increased rate of DNA
damage induced by oxidative stress. Accordingly, the
degree of competition between the SUMO/Ubc9 and
ubiquitin/RAD6 pathways in maintaining chromosomal
integrity should correlate with the mode of nicotine-induced
stress response eventually leading to alterations in cell fate.
This model provides an intriguing mechanism by which
nicotine may prevent or delay apoptosis, although chromo-
somal integrity is compromised (Fig. 6). However, futurestudies are needed to address the molecular mechanisms by
which nicotine induces DNA damage and the types of
linkage ubiquitin molecules form after their nicotine-
induced expression.
Although this model correlates with the findings in the
PFC, it may seem to contradict the effects we observed in
the MBH at 14 days, i.e., the downregulation of ubiquitin/
proteasome and CCT pathways. One of the explanations for
the differential response of brain regions to nicotine may be
compositional differences of the nAChRs. This diversity in
different parts of the brain results in relatively different
sensitization/desensitization profiles for each region and
even nuclei. Therefore, it is possible that the periods of
treatment (e.g., 3 or 14 days) translate into different
exposure periods for the cells in the PFC vs. the MBH.
This asynchrony also may be reflected in the transcriptional
response in the PFC and MBH to nicotine. Furthermore, the
time required for adaptation to a nicotine-altered cellular
environment may differ among brain regions, resulting in
differential needs for the maintenance of cellular homeo-
stasis, hence leading to alternative cell fates.
Finally, an inverse association has been reported between
the prevalence of tobacco smoking and the occurrence of
Alzheimer’s and Parkinson’s diseases [42]. Both of these
diseases have been linked to proteasomal and CCT
deregulation [38,41]. We suggest a possible mechanism
for the inverse association with nicotine is through its effects
on the ubiquitin–proteasomal and CCT pathways (Fig. 6).
Future studies focusing on how and why nicotine is
affecting these gene families hold promise for enhancing
our understanding of the observed inverse association
between nicotine usage and these neurodegenerative dis-
eases, as well as for providing novel mechanisms through
which neurons may be adapting to the actions of nicotine.Acknowledgement
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